Saturday 17 October 2026
Export GRI’s income statement to Excel — free account
GRI Bio, Inc.
In the quarter to June 2026, EPS grew 97.5% and free cash flow grew 54.3%, each against the same quarter a year earlier.
1.38
0.02
−1.43%
Follow GRI
GRI Bio, Inc. (GRI) P/E ratio
As of 16 October 2026, GRI Bio, Inc. (GRI) trades at a P/E ratio of 0.0×. Over the past ten years it has ranged from 0.0× (March 2026) to 0.1× (April 2026); the current reading is higher than 86% of that period. That is below the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2020 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.1×
Ten-year median
0.0×
Current reading's percentile
86
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CLDI Calidi Biotherapeutics, Inc. compare | n/m |
| ADXN Addex Therapeutics Ltd. Sponsored ADR compare | n/m |
| REVB Revelation Biosciences, Inc. compare | n/m |
| SXTP 60 Degrees Pharmaceuticals Inc. compare | n/m |
| EOCN Eocene Ltd. compare | n/m |
| ARAV ARAVIVE, INC compare | n/m |
| APVO Aptevo Therapeutics Inc. compare | 0.0× |
| DCOY Decoy Therapeutics Inc compare | 0.0× |
| GRI GRI Bio, Inc. | 0.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)